Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CStone Pharmaceuticals ( (HK:2616) ) has shared an announcement.
CStone Pharmaceuticals announced a clinical progress update on CS2009, a novel trispecific antibody targeting PD-1, VEGFA, and CTLA-4. The ongoing global multicenter Phase I/II study is enrolling patients in Australia and China, with plans to expand to the United States. CS2009 has shown promising results in safety and efficacy, particularly in patients with advanced solid tumors. The study aims to advance the development of next-generation immuno-oncology therapeutics, potentially positioning CStone as a leader in this field.
More about CStone Pharmaceuticals
CStone Pharmaceuticals, established in 2015, is an innovation-driven biopharmaceutical company focused on developing anti-cancer therapies. The company has launched four innovative drugs and secured approvals for 16 new drug applications covering nine indications. CStone’s pipeline includes promising candidates such as antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.
Average Trading Volume: 12,238,761
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.96B
For an in-depth examination of 2616 stock, go to TipRanks’ Overview page.